Print

Masimo Corporation (MASI) Initiates Limited Market Release of Universal ReSposable™ Pulse Oximetry Sensor System  
10/15/2012 12:23:14 PM

IRVINE, Calif., Oct. 15, 2012 /PRNewswire/ -- Masimo (NASDAQ: MASI) announced today limited market release of the Universal ReSposable Pulse Oximetry Sensor System, offering the Measure-Through Motion and Low Perfusion performance and accuracy of SET®, as well as the comfort of its single-patient-use adhesive sensors with the cost-effectiveness and environmental advantages of a reusable sensor.

The new Universal ReSposable pulse oximetry sensor was created after more than 10 years of research and development with feedback from hundreds of clinicians on what they wanted most in a sensor less waste, more value, and the Masimo SET® performance.

The new ReSposable sensor components sit atop the sensor not embedded reducing risk of pressure points. Patients also can be disconnected from a pulse oximeter without having to carry the sensor cable.

"We've been impressed not only with the reduction in costs, but the ReSposable sensor is helping us meet our environmental, waste-reduction goals," said SuzAnne J Gil, Clinical Resource Manager at San Juan Regional Medical Center in Farmington, New Mexico. "In an era when hospitals are expected to deliver quality care, while controlling costs and carbon footprints, Masimo's ReSposable sensors offer a clear benefit for patients, clinicians and facility administrators."

"The Masimo innovative ReSposable concept should be considered for any clinical unit regarding SpO2 sensor usage because of its sustainability both in terms of cost-control and waste-reduction policies," said Dr. Concha Goni, head of neonatal and pediatric intensive care units at Hospital Virgen del Camino in Pamplona, Spain, where the sensor has been used as part of Masimo's pre-market release testing.

Masimo's Universal ReSposable SpO2 sensors generate up to 90% less waste vs. 34% less waste with reprocessing,* while reducing carbon emissions up to 41% vs. 43% more emissions with reprocessing.**

Disposable pulse oximetry sensors historically have offered the best performance, greatest ease of use, and most comfort, but do generate more waste than reusable sensors. Reusable sensors may offer low environmental impact, but do not offer the same performance, comfort, or reduction of cross-contamination risk as disposable sensors. And third-party reprocessed sensors do not offer the same performance or quality as new sensors, as evidenced by their own indications for use statements. Moreover, reprocessed sensors have a higher carbon footprint than new sensors, due to greater greenhouse gas emissions from transport, reprocessing, and decontamination procedures.

Joe Kiani, CEO and Founder of Masimo, said, "More than ever, hospitals are under pressure to reduce costs and implement green initiatives, while maintaining infection-control practices to protect patients and staff from cross-contamination. While the ultimate way to reduce cost and improve care is through process of care improvements made possible by technologies like SET® and rainbow®, with ReSposable sensors, hospital materials management departments can meet the cost reduction edicts, while helping their hospitals meet their environmental, and safety goals, and most importantly ensure that their patients are provided with accurate monitoring when they need it most."

Contact your local Masimo sales representative for demonstration of the Universal ReSposable Sensors. To locate a Masimo representative or distributor in your area and evaluate the Universal ReSposable SpO2 Sensor System, call 1-800-257-3810 or visit www.masimo.com.

*Waste calculated by sensor weight for 40% reprocessed sensors with a mix of 80% Adult and Pediatric sensors, 20% Neo and infant sensors.

**Carbon footprint comparisons calculated by lbs. CO2 emissions with same reprocess mix as waste. Carbon footprint calculations validated by Carbonfund.org in November, 2011.

About Masimo
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient carehelping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies have shown that Masimo SET® outperforms all other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow SET® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOC), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). In 2008, the company introduced Masimo Patient SafetyNet, a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events. In 2009, Masimo introduced rainbow Acoustic Monitoring, the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa). Masimo's rainbow SET® technology platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options. In 2010, Masimo acquired SEDLine®, a pioneer in the development of innovative brain function monitoring technology and devices. Masimo SET® and Masimo rainbow SET® technologies can also be found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world. Founded in 1989, Masimo has the mission of "Improving Patient Outcome and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications®." Additional information about Masimo and its products may be found at www.masimo.com.

Forward-Looking Statements
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions of the repeatability of clinical results obtained using the Universal ReSposable SpO2 Sensor System, the comfort of the single-patient-use adhesive sensor, its cost-effectiveness, and environmental advantages; and our assumptions that rainbow Universal SuperSensor enables continuous measurement of SpHb, SpCO, SpMet, SpO2 and the new SpfO2 parameter that allows precise oxygen saturation even in the presence of dyshemoglobins, as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Media Contact:
Mike Drummond
Masimo Corporation
Phone: (949) 297-7434
Email: mdrummond@masimo.com

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57,Rad-8, Rad-5,Pulse CO-Oximetry, Pulse CO-Oximeter, Adaptive Threshold Alarm, and SEDLine are trademarks or registered trademarks of Masimo Corporation. The use of the trademarks Patient SafetyNet and PSN are under license from University HealthSystem Consortium.

SOURCE Masimo


//-->